Compare ARES & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARES | GEHC |
|---|---|---|
| Founded | 1997 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Computer Software: Prepackaged Software |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7B | 29.9B |
| IPO Year | 2014 | 2022 |
| Metric | ARES | GEHC |
|---|---|---|
| Price | $115.89 | $65.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $165.50 | $88.38 |
| AVG Volume (30 Days) | 2.1M | ★ 4.3M |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.87% | 0.24% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 0.85 |
| Revenue | $4,755,618,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | N/A | $7.12 |
| Revenue Next Year | $17.59 | $4.45 |
| P/E Ratio | $78.35 | ★ $77.18 |
| Revenue Growth | ★ 28.86 | 4.84 |
| 52 Week Low | $95.80 | $58.75 |
| 52 Week High | $195.26 | $89.77 |
| Indicator | ARES | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 55.23 |
| Support Level | $107.40 | $60.08 |
| Resistance Level | $128.17 | $78.85 |
| Average True Range (ATR) | 5.76 | 1.78 |
| MACD | -1.66 | 0.28 |
| Stochastic Oscillator | 30.52 | 86.48 |
Ares Management is one of the world's largest alternative-asset managers, with $622.5 billion in total assets under management, or AUM, including $384.9 billion in fee-earning AUM, at the end of 2025. The company has four main business segments: credit strategies ($406.9 billion in total AUM and $249.8 billion in fee-earning AUM), private equity, ($25.3 billion/$14.4 billion), real estate/real assets ($139.1 billion/$84.1 billion), and other alternatives ($51.2 billion/$36.6 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries around the globe.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).